Supernus Pharm (SUPN) Stock Price, Quote & News

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 838 2500

Website: www.supernus.com

Address:

9715 Key West Avenue, Rockville, United States

ortega1963 Feb. 20 at 6:31 AM

$SUPN ascending Triangle

0 · Reply

NetworkNewsWire Feb. 17 at 2:05 PM

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A $OTLC $ARWR $MGTX $SUPN $JNJ https://ibn.fm/8zb4f

1 · Reply

Night_Owl_Biotech Feb. 6 at 2:23 AM

Of the 63 commercial-stage non-oncology focused bios with market caps ranging from $750MM to $15B, only 8 are trading higher after the worst 2 days for the XBI since April 2025. $OCUL was up we suspect due to renewed hope for a Sanofi buyout. Recall Sanofi offered $16 per share to acquire OCUL last September. OCUL closed today (6 months later) at $8.91. $SUPN has been quiet (no PR since November) but perhaps SUPN's gains reflect the virtue of diversity. $TWST released Q126 financials Monday after the close. TWST is 1 of the 8 higher the last 2 days. $VALN focuses on vaccines which has been a lousy space (of course excluding DVAX). $ORG had finally been running after trading between $6 & $8 a share since Halloween. One has to wonder if OGN under $8 is a memory. OGN generates $6B/year in sales but has a leveraged capital structure. If OGN ever traded at peer multiples...

1 · Reply

RadcliffeRanges Feb. 4 at 9:38 AM

$SUPN specialty pharma, generic competition

0 · Reply

OfficialStocktwitsUser Jan. 30 at 1:18 PM

$SUPN RSI: 32.73, MACD: -0.0402 Vol: 1.02, MA20: 49.98, MA50: 48.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

quietpiggy Jan. 9 at 8:08 PM

$SUPN I am curious if the company is as bad to work for as they say online. You would be hard pressed to find a good review on Glassdoor. Namely low salary and toxic work environment. Regional Directors (middle management) are cheerleaders and micromanagers. People are saying ‘RUN AWAY!’ online. Someone here has to share the tea.

1 · Reply

quietpiggy Jan. 9 at 8:05 PM

$SUPN who here works for Supernus? There’s gotta be a sales rep on this thread.

0 · Reply

Night_Owl_Biotech Jan. 6 at 12:57 AM

The attachment compares $BCRX revenue multiples (valuation as a multiple of projected revenues) to peer commercial-stage non-oncology focused bios with similar revenue projections. BCRX's gross margins (97% in FY2024) are the highest of all of these peers yet BCRX trades at a meaningfully lower multiple of projected revenues. As we understand it, Orladeyo generics are not to be available until FY2040. $SUPN $TARS trade at meaningfully higher multiples yet are supposed to generate, more or less, the same revenue dollars. $ARQT is projected to generate less revenues $CPRX ? We followed BCRX for years but have not kept up. Any guidance from BCRX bulls would be genuinely appreciated. BCRX is one of the very few commercial-stage non-oncology focused bios not trading meaningfully higher than the XBI lows of early April 2025. We're aware BCRX's enterprise value is roughly $0.05B higher than its market cap. This is not investment advice.

5 · Reply

OfficialStocktwitsUser Jan. 5 at 5:58 PM

$SUPN RSI: 65.21, MACD: 0.8502 Vol: 2.17, MA20: 48.97, MA50: 48.47 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsNews Dec. 19 at 6:38 PM

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order $PSIL $SUPN $HELP.DL0126 $ATAI https://stocktwits.com/news/equity/markets/atai-beckley-supernus-jump-as-wall-street-flags-psychedelics-tailwinds-from-trump-marijuana-order/cLe02tNREtb

0 · Reply

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

Feb 9, 2026, 11:14 AM EST - 14 days ago

Lunai Bioworks, Inc. Issues Letter to Shareholders

Feb 1, 2026, 7:59 AM EST - 22 days ago

Supernus: Outlook For 2026 Positive, Upholding Buy Rating

Jan 15, 2026, 10:31 AM EST - 5 weeks ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Dec 8, 2025, 3:57 PM EST - 2 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Dec 3, 2025, 4:05 PM EST - 2 months ago

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Nov 21, 2025, 4:06 PM EST - 3 months ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 4:05 PM EST - 3 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Nov 5, 2025, 12:36 AM EST - 3 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 3 months ago

Supernus Announces Third Quarter 2025 Financial Results

Oct 21, 2025, 5:00 PM EDT - 4 months ago

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Sep 17, 2025, 4:05 PM EDT - 5 months ago

Supernus Pharmaceuticals: Heading In The Right Direction

Aug 27, 2025, 4:15 PM EDT - 6 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

Aug 5, 2025, 6:18 PM EDT - 7 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Supernus Announces Second Quarter 2025 Financial Results

Jul 31, 2025, 8:44 AM EDT - 7 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Jul 28, 2025, 8:25 AM EDT - 7 months ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Jul 22, 2025, 4:30 PM EDT - 7 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

Jul 14, 2025, 4:25 PM EDT - 8 months ago

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SAGE

Jun 16, 2025, 5:31 PM EDT - 9 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

SAGE

Jun 16, 2025, 7:14 AM EDT - 9 months ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

SAGE

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

May 29, 2025, 8:30 AM EDT - 9 months ago

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 28, 2025, 4:05 PM EDT - 9 months ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025, 4:05 PM EDT - 9 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 10:55 PM EDT - 10 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:08 PM EDT - 10 months ago

Supernus Announces First Quarter 2025 Financial Results

Apr 23, 2025, 5:14 PM EDT - 10 months ago

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

ortega1963 Feb. 20 at 6:31 AM

$SUPN ascending Triangle

0 · Reply

NetworkNewsWire Feb. 17 at 2:05 PM

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A $OTLC $ARWR $MGTX $SUPN $JNJ https://ibn.fm/8zb4f

1 · Reply

Night_Owl_Biotech Feb. 6 at 2:23 AM

1 · Reply

RadcliffeRanges Feb. 4 at 9:38 AM

$SUPN specialty pharma, generic competition

0 · Reply

OfficialStocktwitsUser Jan. 30 at 1:18 PM

0 · Reply

quietpiggy Jan. 9 at 8:08 PM

1 · Reply

quietpiggy Jan. 9 at 8:05 PM

$SUPN who here works for Supernus? There’s gotta be a sales rep on this thread.

0 · Reply

Night_Owl_Biotech Jan. 6 at 12:57 AM

5 · Reply

OfficialStocktwitsUser Jan. 5 at 5:58 PM

0 · Reply

StocktwitsNews Dec. 19 at 6:38 PM

0 · Reply

Gemola Dec. 19 at 6:24 PM

$SUPN Boolish first target $55.00 ++

0 · Reply

JarvisFlow Dec. 19 at 2:53 PM

Stifel has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Hold with a price target of 55.

0 · Reply

BillionerOfKing Dec. 11 at 11:19 PM

$SUPN Current Stock Price: $46.55 Contracts to trade: $45 SUPN Dec 19 2025 Call Entry: $1.25 Exit: $2.19 ROI: 75% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

oooo_O Nov. 25 at 3:46 PM

$SUPN 🚀🚀🚀🚀🚀🚀

0 · Reply

nikitatrades Nov. 16 at 12:27 PM

🚀 $SUPN Token (Superp) Analysis! 🚀 ✨ Innovative Trading: SUP fuels Superp, a DEX offering "No Liquidation" high-leverage trading for volatile assets like meme coins. Imagine a trading safety net, reducing abrupt losses! 🗳️ Community Power: Holding SUP gives you a voice in platform governance, letting you shape its future like a shareholder, plus staking rewards. 📈 Growing Ecosystem: With $37B+ volume (Q3 2025), and plans for Solana expansion, Superp is expanding its reach. ⚠️ Supply Dynamics: A large portion of SUP's 1B tokens are still locked, so future unlocks could create selling pressure. #Crypto #DeFi #Superp

0 · Reply

SuperGreenToday Nov. 11 at 8:56 PM

$SUPN Share Price: $46.14 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.39 – $4.14 Potential Upside: 51% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

fullobullz Nov. 7 at 8:19 PM

$CING Anyone else think $80 may actually be in line if they get PUFDA or im I just an idiot? $CING already has patents in these countries: Australia, Canada, Israel, and Europe. Add pending US, Korea and Hong Kong and your looking at a nice market share lock. $SUPN $AXSM have mc over $1B and I think $CING could hit that as well once given pufda. Interested to hear everyone's thoughts for long term

2 · Reply

d_risk Nov. 7 at 12:54 AM

$SUPN - Supernus Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors SUPN updates tariff risk to focus on newly announced tariffs for pharmaceuticals, drops risks tied to 2025 drug pricing Executive Orders, and adds new warnings about costly, distracting legal actions. #Pharmaceuticals #RegulatoryChanges #LegalRisk #DrugPricing #TariffRisk 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-Q/2025-11-06

0 · Reply

kgpittm Nov. 5 at 6:01 PM

$SUPN Lots of profit taking going on here on a quarter where they took some one-time charges that impacted bottom line, but actually improved guidance for the year. Big yellow flag was actually that they are having supply issues due to the success of one of their newer products. They need to get that resolved quickly so that revenue growth can continue.

2 · Reply

DonCorleone77 Nov. 4 at 10:40 PM

$SUPN Supernus reports Q3 EPS (80c) vs. 69c last year -- Q3 revenue $192.1M, consensus $180.22M. -- Raises FY25 revenue view to $685M-$705M from $670M-$700M, consensus $702.59M. -- Raises FY25 adjusted operating earnings view to $125M-$145M from $105M-$135M.

0 · Reply

Market Cap	2.92B
Revenue (ttm)	661.82M
Net Income (ttm)	73.87M
EPS (ttm)	N/A
PE Ratio	24.11
Forward PE	26.54
Profit Margin	11.16%
Debt to Equity Ratio	0.00

Volume	563,504
Avg Vol	668,552
Day's Range	N/A - N/A
Shares Out	57.34M
Stochastic %K	56%
Beta	0.71
Analysts	Strong Sell
Price Target	$61.33